T2 Biosystems, Inc. provided revenue guidance for the year 2023. For the year, Company now expects total sepsis and related product revenue of $9.5 million to $10.5 million, representing growth of 13% to 25%, compared to $8.4 million in 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.29 USD | -5.09% | -16.54% | -31.63% |
05-15 | Sector Update: Health Care Stocks Advance Late Wednesday Afternoon | MT |
05-15 | T2 Biosystems Shares Rise After CRG Servicing Ups Stake | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.63% | 73.21M | |
+9.48% | 222B | |
+13.72% | 195B | |
+23.79% | 148B | |
+33.39% | 113B | |
+4.75% | 66.45B | |
+15.59% | 53.11B | |
+3.16% | 50.03B | |
-4.35% | 38.8B | |
-1.27% | 34.85B |
- Stock Market
- Equities
- TTOO Stock
- News T2 Biosystems, Inc.
- T2 Biosystems, Inc. Provides Revenue Guidance for the Year 2023